Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to outperform for the balance of 2014. Here are some of the top…
After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical stocks in early February. The largest upswings happened to BioMarin Pharmaceutical and…
Most Wall Street firms run model portfolios for their institutional and retail clients. Here are stocks that recently were added to the Piper Jaffray Model Portfolio.
In a new research report, the analysts at Deutsche Bank unveil their "what to buy now ?" list for large cap stocks. We picked a top names from each sector listed in…
With top biotechnology and health care companies from around the world attending the Leerink Global Healthcare, it is a good chance for investors to get timely updates on the top stocks and…
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is rising on Monday after two analysts made positive calls on the biotech giant. As a reminder, Gilead is now the world’s largest pure-play biotech as the…
Jon C. Ogg These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on is Monday, February 10, 2014. They include Fairway Group, J.P. Morgan, Red Robin and Vodafone.
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) is the biggest biotech company in America, and it is one of the top performers for 2013. Despite having a market cap of well over $100 billion…
Jon C. Ogg Biogen Idec surprised investors Wednesday with weaker-than-expected guidance for 2014 earnings. Amgen beat estimates late Tuesday. Celgene and Gilead Sciences report earnings on Thursday.
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board.…
Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going forward but can stay intact. They think the fundamental backdrop is very…
The U.S. equity strategy team at UBS has a positive view on stocks heading into 2014, particularly technology, financials and industrials. Here are the names they feel have the absolute greatest chance…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.
The Cowen biotechnology team has a list of top 10 surprises that are specific to the very hot biotechnology sector.
